Longevity Biomedical Deal Approved by Denali Capital Shareholders

Denali Capital Shareholders Approve Longevity Biomedical Deal

In an 8-K filing, Denali Capital Acquisition stated that shareholders approved the merger with Longevity Biomedical. The SPAC reported that 4,440,202 shares were redeemed. The goal is to advance breakthrough technologies in pharmaceuticals, health monitoring, and digital health solutions to extend human life. A year ago, the acquisition had a pro forma equity worth of about $236.2 million.

Read more on https://news.spacconference.com/2024/01/10/denali-capital-shareholders-approve-longevity-biomedical-deal/

Shanda Consult has been working with SPACs for many years, and our network of SPAC executives has deep experience in the sector. If you need to learn more about how to successfully use a SPAC structure and perhaps wish to set up your own SPAC, we are here to help.

Please contact us with any questions you may have.